VISEN Pharmaceuticals (HKG:2561)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
25.20
0.00 (0.00%)
Apr 29, 2026, 4:08 PM HKT
-42.47%
Market Cap 2.75B
Revenue (ttm) 151.34K
Net Income (ttm) -282.01M
Shares Out 109.04M
EPS (ttm) -2.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,400
Average Volume 14,770
Open 24.66
Previous Close 25.20
Day's Range 24.60 - 25.20
52-Week Range 24.00 - 54.00
Beta n/a
RSI 39.29
Earnings Date Apr 30, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy f... [Read more]

Sector Healthcare
Founded 2018
Employees 82
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2561
Full Company Profile

Financial Performance

In 2025, VISEN Pharmaceuticals's revenue was 136,000, a decrease of -95.10% compared to the previous year's 2.78 million. Losses were -253.42 million, 39.1% more than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.